1. ¹Faculty of Medicine, University of Oslo, Oslo, Norway
2. ²Department of Clinical Cancer Research, Rikshospitalet-Radiumhospitalet Trust, Oslo, Norway
3. ³Department of Pathology, Rikshospitalet-Radiumhospitalet Trust, Oslo, Norway
4. ⁴Department of Surgical Oncology, Rikshospitalet-Radiumhospitalet Trust, Oslo, Norway

Correspondence: Dr J Oldenburg, E-mail: jan.oldenburg@medisin.uio.no

Received 2 November 2005; Revised 21 December 2005; Accepted 30 January 2006; Published online 28 February 2006.

Abstract

The purpose of this study was to explore the incidence of late relapse in patients with malignant germ cell tumour (MGCT) in a population-based series, with emphasis on the mode of detection, survival, and the relevance of histological findings. The clinical records from a population-based cohort of patients with seminoma (n=1123) or non-seminoma (n=826) were evaluated for late relapses. Twenty-five patients developed a late relapse. The cumulative 10-year incidence rate was 1.3%. All 10 seminoma patients, but only eight of 15 non-seminoma patients relapsed with vital malignant tumour (P=0.02). Teratoma or necrosis was found in seven of nine primarily chemotherapy-treated non-seminoma patients with normal tumour markers at late relapse. Six of nine patients operated with limited retroperitoneal lymph node dissection as part of the primary treatment had relapsed retroperitoneally outside the original operation field. The 10-year cause-specific survival was 68% in all patients, 50% in patients relapsing with vital malignant tumour and 100% in those with teratoma/ necrosis before or after salvage chemotherapy. The 10-year incidence rate of late relapses of 1.3% might reflect the true incidence rate in a population-based cohort of MGCT patients, with cure in at least half of them.